Merck (MRK) animal health chief DeLuca sells 6,050 shares

Rhea-AI Filing Summary

Merck & Co., Inc. executive Richard R. DeLuca, EVP & President, Merck Animal Health, reported selling a total of 6,050 shares of Merck common stock on 2026-08-06 in three open-market transactions. The reported per-share prices are weighted averages, with actual trade prices within disclosed ranges around $130–$131 per share.

Insider Trade Summary

Net Seller: 6,050 shares

Net Sell 3 txns

Insider DeLuca Richard R.

Role EVP&Pres, Merck Animal Heallth

Sold 6,050 shs ($789K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	805	$131.0216	$105K
Sale	Common Stock F2	4,945	$130.2312	$644K
Sale	Common Stock F3	300	$131.0233	$39K

Holdings After Transaction: Common Stock — 155,487.07 shares (Direct)

Footnotes (3)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.0700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.0000 to $130.9200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.0300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

Key Figures

Shares sold (trade 1): 805 shares at $131.0216 per share Shares sold (trade 2): 4,945 shares at $130.2312 per share Shares sold (trade 3): 300 shares at $131.0233 per share +1 more

4 metrics

Shares sold (trade 1) 805 shares at $131.0216 per share Common Stock sale on 2026-08-06, code S

Shares sold (trade 2) 4,945 shares at $130.2312 per share Common Stock sale on 2026-08-06, code S

Shares sold (trade 3) 300 shares at $131.0233 per share Common Stock sale on 2026-08-06, code S

Total shares sold 6,050 shares Aggregate of three Common Stock sales on 2026-08-06

Key Terms

weighted average price, open market or private transaction, Common Stock

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"Transaction code "S" described as Sale in open market or private transaction"

Common Stock financial

"Security title reported for all transactions is Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/10/2026 - 04:28 PM Accepted by SEC EDGAR 08/10/2026 - 04:28 PM Learn about SEC filing dates

FAQ

What insider activity did Merck (MRK) report for Richard R. DeLuca?

Merck reported that Richard R. DeLuca, EVP & President, Merck Animal Health, sold 6,050 shares of common stock on 2026-08-06 in three open-market transactions at weighted-average prices around $130–$131 per share.

How many Merck (MRK) shares did Richard R. DeLuca sell in each transaction?

Richard R. DeLuca reported three sales: 805 shares, 4,945 shares, and 300 shares of Merck common stock. All occurred on 2026-08-06 and were reported as open-market or private sale transactions.

At what prices were Richard R. DeLuca’s Merck (MRK) shares sold?

The reported weighted-average prices were $131.0216, $130.2312, and $131.0233 per share. Footnotes state these are weighted averages for multiple trades executed within narrower price ranges around those levels.

Were Richard R. DeLuca’s Merck (MRK) sales single trades or multiple trades?

Each reported sale represents multiple transactions. Footnotes explain the prices are weighted averages, with individual trades executed within specified price ranges between about $130.00 and $131.07 per share.

What type of transactions did Merck (MRK) disclose for Richard R. DeLuca?

All three reported transactions are sales of common stock coded "S," described as sales in open market or private transactions. The filing shows a total of 6,050 shares sold and no derivative exercises or gifts.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeLuca Richard R.

(Last) (First) (Middle)

MERCK & CO., INC.

126 EAST LINCOLN AVENUE

(Street)

RAHWAY NEW JERSEY 07065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [ MRK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP&Pres, Merck Animal Heallth

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2026		S		805	D	$131.0216(1)	160,732.07	D
Common Stock	08/06/2026		S		4,945	D	$130.2312(2)	155,787.07	D
Common Stock	08/06/2026		S		300	D	$131.0233(3)	155,487.07	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.0700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.0000 to $130.9200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.0300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

	/s/ Kelly E. W. Grez as Attorney-in-Fact for Richard R. DeLuca, Jr.	08/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)